Handelsbanken Fonder’s SpringWorks Therapeutics SWTX Stock Holding History

Handelsbanken Fonder’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21,200	Closed	-$996K	–	1521
2025 Q2	$996K	Sell	21,200 -2,200	-9%	-$97.9K	﹤0.01%	961
2025 Q1	$1.03M	Hold	23,400	–	–	﹤0.01%	928
2024 Q4	$845K	Hold	23,400	–	–	﹤0.01%	1043
2024 Q3	$750K	Buy	23,400 +3,600	+18%	+$135K	﹤0.01%	1062
2024 Q2	$746K	Buy	19,800 +2,400	+14%	+$101K	﹤0.01%	974
2024 Q1	$856K	Buy	17,400 +5,600	+47%	+$259K	﹤0.01%	901
2023 Q4	$431K	Buy	+11,800	New	+$308K	﹤0.01%	1218
2022 Q2	–	Sell	-5,900	Closed	-$333K	–	1689
2022 Q1	$333K	Hold	5,900	–	–	﹤0.01%	1463
2021 Q4	$366K	Hold	5,900	–	–	﹤0.01%	1542
2021 Q3	$374K	Hold	5,900	–	–	﹤0.01%	1514
2021 Q2	$486K	Buy	+5,900	New	+$448K	﹤0.01%	1404
2021 Q1	–	Sell	-3,300	Closed	-$239K	–	1587
2020 Q4	$239K	Buy	+3,300	New	+$212K	﹤0.01%	1476

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Handelsbanken Fonder's SWTX Position: Q3 2025 in Review

Handelsbanken Fonder sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 21,200 shares — an estimated $996K sold.

Handelsbanken Fonder first reported a position in SWTX in Q4 2020 and held it in 12 quarters. The position peaked at $1.03M in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Handelsbanken Fonder reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Handelsbanken Fonder sold 21,200 SpringWorks Therapeutics shares in Q3 2025, an estimated $996K.
Handelsbanken Fonder first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 12 quarters.
Handelsbanken Fonder's SpringWorks Therapeutics position peaked at $1.03M in Q1 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Handelsbanken Fonder's 13F filing for Q3 2025, filed 12 Nov 2025.